PRESS RELEASE: Exelixis Announces Closing of Public Offering of Common Stock

Exelixis Announces Closing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Sept. 13 -- Exelixis today announced the closing of its public offering of 7,000,000 shares of common stock. The net proceeds of the offering are approximately $71.8 million, after deducting estimated offering expenses. All of the shares in the offering are being sold by Exelixis. Exelixis has also granted the underwriter a 30-day option to purchase up to an additional 1,050,000 shares of common stock. Goldman, Sachs & Co. acted as the sole underwriter for the offering.

The offering is being made pursuant to an effective automatic shelf registration statement. The offering may be made only by means of a prospectus supplement and the accompanying prospectus, copies of which may be obtained by sending a request to: Goldman, Sachs & Co., Attn: Prospectus Department, 85 Broad Street, New York, New York 10004, Fax: 212-902-9316 or Email at [email protected].

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. Exelixis and the Exelixis logo are registered U.S. trademarks.

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.